1099: Sinopharm Group Co. Ltd. - Summary | Jitta

Sinopharm Group Co. Ltd.

HKG:1099

Price
HK$23.75
Loss Chance
42.3%
6.63JITTA SCORE
74.51%Under Jitta Line
Jitta Ranking
39 / 192
346 / 2,389
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (67)
Recent Business Performance (81)
Financial Strength (94)
Return to Shareholders (56)
Competitive Advantage (62)
Jitta Signs
Revenue and EarningConsistent Growth in the past 5 years
Operating MarginConsistent
Debt LevelLow Long Term Debt
Interest Coverage RatioVery Good
Key Stats
Jitta Score
Jitta Line
6.63
74.51%
3.58
245.67%
Health Care Distributors
1.47
100.00%
5.06
31.48%
4.90
13.64%
COMPANY DESCRIPTION
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People’s Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.